The Experts below are selected from a list of 48657 Experts worldwide ranked by ideXlab platform
Andrés Tittarelli - One of the best experts on this subject based on the ideXlab platform.
-
The immunological response and Post-Treatment Survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
Cancer Immunology Immunotherapy, 2013Co-Authors: Claudia Durán-aniotz, Gabriela Segal, Lorena Salazar, Cristián Pereda, Cristián Falcón, Fabián Tempio, Raquel Aguilera, Rodrigo González, Claudio Pérez, Andrés TittarelliAbstract:Introduction Immunization with autologous dendritic cells (DCs) loaded with a heat shock-conditioned allogeneic melanoma cell lysate caused lysate-specific delayed type hypersensitivity (DTH) reactions in a number of patients. These responses correlated with a threefold prolonged long-term Survival of DTH^+ with respect to DTH^− unresponsive patients. Herein, we investigated whether the immunological reactions associated with prolonged Survival were related to dissimilar cellular and cytokine responses in blood. Materials and methods Healthy donors and melanoma patient’s lymphocytes obtained from blood before and after vaccinations and from DTH biopsies were analyzed for T cell population distribution and cytokine release. Results/discussion Peripheral blood lymphocytes from melanoma patients have an increased proportion of Th3 (CD4^+ TGF-β^+) regulatory T lymphocytes compared with healthy donors. Notably, DTH^+ patients showed a threefold reduction of Th3 cells compared with DTH^− patients after DCs vaccine Treatment. Furthermore, DCs vaccination resulted in a threefold augment of the proportion of IFN-γ releasing Th1 cells and in a twofold increase of the IL-17-producing Th17 population in DTH^+ with respect to DTH^− patients. Increased Th1 and Th17 cell populations in both blood and DTH-derived tissues suggest that these profiles may be related to a more effective anti-melanoma response. Conclusions Our results indicate that increased proinflammatory cytokine profiles are related to detectable immunological responses in vivo (DTH) and to prolonged patient Survival. Our study contributes to the understanding of immunological responses produced by DCs vaccines and to the identification of follow-up markers for patient outcome that may allow a closer individual monitoring of patients.
-
the immunological response and Post Treatment Survival of dc vaccinated melanoma patients are associated with increased th1 th17 and reduced th3 cytokine responses
Cancer Immunology Immunotherapy, 2013Co-Authors: Claudia Durananiotz, Gabriela Segal, Lorena Salazar, Cristián Pereda, Cristián Falcón, Fabián Tempio, Raquel Aguilera, Rodrigo González, Claudio A. Perez, Andrés TittarelliAbstract:Introduction Immunization with autologous dendritic cells (DCs) loaded with a heat shock-conditioned allogeneic melanoma cell lysate caused lysate-specific delayed type hypersensitivity (DTH) reactions in a number of patients. These responses correlated with a threefold prolonged long-term Survival of DTH+ with respect to DTH− unresponsive patients. Herein, we investigated whether the immunological reactions associated with prolonged Survival were related to dissimilar cellular and cytokine responses in blood.
-
The immunological response and Post-Treatment Survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
Cancer immunology immunotherapy : CII, 2012Co-Authors: Claudia Durán-aniotz, Gabriela Segal, Lorena Salazar, Cristián Pereda, Cristián Falcón, Fabián Tempio, Raquel Aguilera, Rodrigo González, Claudio A. Perez, Andrés TittarelliAbstract:Introduction Immunization with autologous dendritic cells (DCs) loaded with a heat shock-conditioned allogeneic melanoma cell lysate caused lysate-specific delayed type hypersensitivity (DTH) reactions in a number of patients. These responses correlated with a threefold prolonged long-term Survival of DTH+ with respect to DTH− unresponsive patients. Herein, we investigated whether the immunological reactions associated with prolonged Survival were related to dissimilar cellular and cytokine responses in blood.
Anastasia Hadjivassiliou - One of the best experts on this subject based on the ideXlab platform.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus
CardioVascular and Interventional Radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard Lim, Peter Tae Wan Kim, Anastasia Hadjivassiliou, David M. LiuAbstract:Purpose Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. Materials and Methods This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Results Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. Conclusion In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardiovascular and interventional radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard John Lim, Peter Tae Wan Kim, Anastasia HadjivassiliouAbstract:Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
Leandro Cardarelli-leite - One of the best experts on this subject based on the ideXlab platform.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus
CardioVascular and Interventional Radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard Lim, Peter Tae Wan Kim, Anastasia Hadjivassiliou, David M. LiuAbstract:Purpose Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. Materials and Methods This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Results Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. Conclusion In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardiovascular and interventional radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard John Lim, Peter Tae Wan Kim, Anastasia HadjivassiliouAbstract:Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
David M. Liu - One of the best experts on this subject based on the ideXlab platform.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus
CardioVascular and Interventional Radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard Lim, Peter Tae Wan Kim, Anastasia Hadjivassiliou, David M. LiuAbstract:Purpose Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. Materials and Methods This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Results Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. Conclusion In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
John Chung - One of the best experts on this subject based on the ideXlab platform.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus
CardioVascular and Interventional Radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard Lim, Peter Tae Wan Kim, Anastasia Hadjivassiliou, David M. LiuAbstract:Purpose Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. Materials and Methods This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Results Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. Conclusion In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.
-
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardiovascular and interventional radiology, 2020Co-Authors: Leandro Cardarelli-leite, John Chung, Darren Klass, Vladimir Marquez, Frank Chou, Henry Walton, Howard John Lim, Peter Tae Wan Kim, Anastasia HadjivassiliouAbstract:Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare Survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization. This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right, left, and/or main portal vein tumor thrombus, preserved liver function (Child–Pugh class ≤ B7), and good performance status (Eastern Cooperative Oncology Group score ≤ 1) treated with yttrium-90 microspheres from 2011 to 2018 with ablative intent transarterial radioembolization (A-TARE), or conventional technique (cTARE). Statistical models were used to compare overall Survival, Post-Treatment Survival, toxicities, and prognosticators of response. Fifty-seven patients were included (21 [36.8%] ablative and 36 [63.2%] conventional intent). Median overall Survival was 15.7 months. Compared to conventional Treatment, ablative radioembolization was associated with longer median overall Survival (45.3 vs 18.2 months; P = 0.003), longer Post-Treatment Survival (19.1 vs 4.9 months; P = 0.005), a 70% lower risk of death (hazard ratio 0.30; 95% confidence interval, 0.13–0.70; P = 0.005), and improved 4-year Survival (53.9% vs 11.2%). Overall Survival did not differ significantly between Treatment with resin and glass microspheres (27.5 vs 22.2 months; P = 0.62). Acceptable hepatic toxicities were observed after yttrium-90 administration, without statistical differences between the groups. In patients with advanced hepatocellular carcinoma and portal vein tumor thrombus, A-TARE is associated with longer Survival than cTARE. Neither modality is associated with deleterious effects on liver function.